Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1002/ana.26144 http://scihub22266oqcxt.onion/10.1002/ana.26144 34114269!?!34114269 Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=34114269&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       Ann+Neurol 2021 ; 90 (2): 315-318 Nephropedia Template TP {{tp|p=34114269|t=2021. Guillain-Barre Syndrome Variant Occurring after SARS-CoV-2 Vaccination |pdf=|usr=}}{{34114269}} gab.com Text Guillain-Barre Syndrome Variant Occurring after SARS-CoV-2 Vaccination JO: Ann Neurol http://www.kidney.de/pget.php?&tw=1&pmid=34114269 #FOAvip Although SARS-CoV-2 vaccines are very safe, we report 4 cases of the bifacial weakness with paresthesias variant of Guillain-Barre syndrome (GBS) occurring within 3 weeks of vaccination with the Oxford-AstraZeneca SARS-CoV-2 vaccine. This rare neurological syndrome has previously been reported in association with SARS-CoV-2 infection itself. Our cases were given either intravenous immunoglobulin, oral steroids, or no treatment. We suggest vigilance for cases of bifacial weakness with paresthesias variant GBS following vaccination for SARS-CoV-2 and that postvaccination surveillance programs ensure robust data capture of this outcome, to assess for causality. ANN NEUROL 2021;90:315-318. Twit Text FOAVip Guillain-Barre Syndrome Variant Occurring after SARS-CoV-2 Vaccination ????Ann Neurol http://www.kidney.de/pget.php?&tw=1&pmid=34114269 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34114269 #FOAvip English Wikipedia <ref>{{Cite pmid|34114269}}</ref> Guillain-Barre Syndrome Variant Occurring after SARS-CoV-2 Vaccination #MMPMID34114269 Allen CM; Ramsamy S; Tarr AW; Tighe PJ; Irving WL; Tanasescu R; Evans JR Ann Neurol 2021[Aug]; 90 (2): 315-318 PMID34114269show ga Although SARS-CoV-2 vaccines are very safe, we report 4 cases of the bifacial weakness with paresthesias variant of Guillain-Barre syndrome (GBS) occurring within 3 weeks of vaccination with the Oxford-AstraZeneca SARS-CoV-2 vaccine. This rare neurological syndrome has previously been reported in association with SARS-CoV-2 infection itself. Our cases were given either intravenous immunoglobulin, oral steroids, or no treatment. We suggest vigilance for cases of bifacial weakness with paresthesias variant GBS following vaccination for SARS-CoV-2 and that postvaccination surveillance programs ensure robust data capture of this outcome, to assess for causality. ANN NEUROL 2021;90:315-318. |COVID-19 Vaccines/administration & dosage/*adverse effects[MESH] |Glucocorticoids/administration & dosage[MESH] |Guillain-Barre Syndrome/*chemically induced/*diagnosis/drug therapy[MESH] |Humans[MESH] |Immunoglobulins, Intravenous/administration & dosage[MESH] |Male[MESH] |Middle Aged[MESH] |Prednisolone/administration & dosage[MESH] |Vaccination/adverse effects[MESH]Guillain-Barre Syndrome Variant Occurring after SARS-CoV-2 Vaccination(epmc).pdf DeepDyve Pubget Overpricing